Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Mega Buana Journal of Nursing The Health Researchers Journal
Gisman, Rahmiaty
Unknown Affiliation
Health Professions Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Penggunaan Obat Antihipertensi pada Pasien Rawat Inap di RSUD Lakipadada Periode 2023-2024 Asmal, Adhitama; Gisman, Rahmiaty; Aswandi
Mega Buana Journal of Nursing Vol. 3 No. 2 (2024): Mega Buana Journal of Nursing
Publisher : LPPM Universitas Mega Buana Palopo

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59183/170a1d66

Abstract

Hipertensi merupakan suatu penyakit yang ditandai dengan peningkatan tekanan darah sistolik 140mmHg dan tekanan darah diastolik lebih dari 90 mmHg pada dua kali pengukuran dengan selang waktu lima menit dalam keadaan cukup istirahat/ tenang. Penelitian ini bertujuan untuk mengetahui gambaran penggunaan obat antihipertensi pada pasien rawat inap di RSUD Lakipadada periode 2023-2024. Penelitian merupakan penelitian deskriptif data yang digunakan dalam penelitian di ambil secara retrospektif dengan menggunakan data sekunder berupa rekam medik pasien hipertensi yang diperoleh 100 kasus pasien rawat inap Hipertensi dengan jumlah 65 (65%) kasus hipertensi paling banyak terjadi pada peasien perempuan dan hanya 35 (35%) kasus yang terjadi pada pasien laki-laki. Pasien dengan usia ≥60 tahun paling banyak terjadi kasus Hipertensi yaitu 44 (44%) kasus. Persentase penggunaan antihipertensi yang paling banyak digunakan adalah Golongan CCB (amlodipin) yaitu sebanyak 44 (80,76%) sedangkan kombinasi antihipertensi yang paling banyak digunakan adalah kombinasi dua golongan antihipertensi yaitu golonganCCB-ARB sebanyak 18 (18%) kasus.
INNOVATION AND CHALLENGES IN THE DEVELOPMENT OF BIOSIMILARS: GLOBAL REGULATIONS AND THEIR APPLICATION IN CANCER THERAPY (2025) Nurvianthi, Riska Yuli; Gisman, Rahmiaty
The Health Researcher's Journal Vol. 2 No. 3 (2025): The Health Researchers Journal
Publisher : The SDGS Forum Communication

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.00000/q0rcsm38

Abstract

Biosimilars offer a more affordable alternative to reference biologic drugs, providing a solution to reduce treatment costs, particularly in cancer therapy. However, their development faces challenges, especially regarding regulatory differences between countries, which delay their global distribution. This article reviews the latest developments in biosimilar development, particularly in cancer treatment. The primary focus is on the regulatory challenges encountered in the development and distribution of biosimilars, as well as their application in cancer therapy, with emphasis on the acceptance challenges faced by healthcare professionals and patients. This literature review examines recent studies on biosimilars, including regulatory approval processes, clinical applications, and the economic impact on cancer treatment. The analysis also compares regulations across countries and highlights the success of biosimilars in replacing reference biologic drugs such as trastuzumab and rituximab. While innovations in advanced statistical methods have been implemented to expedite the approval process, inconsistent regulations across countries remain a significant barrier. Biosimilars have proven effective in replacing more expensive biologic drugs, but challenges in acceptance by the medical community and patients persist. Some countries have begun accepting biosimilars as alternatives, though regulatory gaps and uncertainties about long-term efficacy continue to pose obstacles. The development of biosimilars has the potential to reduce cancer treatment costs, but regulatory challenges and acceptance by healthcare professionals and patients must be addressed. Further research is needed to explore long-term effectiveness and harmonize global regulations to accelerate biosimilar adoption in cancer therapy.
Co-Authors Asmal, Adhitama ASWANDI Riska Yuli Nurvianthi